MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Net increase(decrease) in cash and cash...-$25,604K (6.51%↑ Y/Y)Share-based compensationexpense$3,049K (-46.06%↓ Y/Y)Accounts payable,accrued and other...$1,832K (163.70%↑ Y/Y)Amortization of right-of-useasset - operating$101K (-46.56%↓ Y/Y)Prepaid and other assets-$89K (91.58%↑ Y/Y)Depreciation andamortization$87K (-62.98%↓ Y/Y)Proceeds from theissuance of class a common...$4,000K Proceeds from sale ofstock under the...$203K Net cash used inoperating activities-$10,354K (62.04%↑ Y/Y)Net cash used ininvesting activities-$9,870K (-31738.71%↓ Y/Y)Net cash provided by(used in) financing...-$5,380K (-6887.01%↓ Y/Y)Canceled cashflow$5,158K Canceled cashflow$4,203K Net loss-$15,346K (50.99%↑ Y/Y)Purchases of marketablesecurities$9,867K Purchases of property andequipment$3K (-90.32%↓ Y/Y)Payment of issuancecosts associated with...$9,583K Lease liabilities-$136K (48.09%↑ Y/Y)Accretion of discount onmarketable securities, net$30K
Cash Flow

OnKure Therapeutics, Inc. (OKUR)

OnKure Therapeutics, Inc. (OKUR)

source: myfinsight.com